Beacon lights path to approval for vision loss gene therapy
Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa successfully improved visual acuity in a pivotal trial, setting up the biotech to seek regulatory approval for the rare inherited vision-loss disease.